Rhenium-186/188 Labeled HSA Microspheres via Tricarbonyl Precursor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for labeling human serum albumin (HSA) microspheres with rhenium-188 (188Re) suffer from low in vitro stability, with particle-bound radioactivity decreasing to 86% within 48 hours, potentially causing side effects due to tin chloride release.
Innovation Solution
Employing 186/188Re(I)-tricarbonyl ion as a precursor for direct labeling of HSA microspheres, which forms covalent bonds with histidine or cysteine groups, enhancing stability and using a kit with three vials for synthesis and labeling, maintaining above 95% radioactivity after 72 hours.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If tin chloride is used for labeling HSA microspheres with 188Re, then labeling yield is improved, but in vitro stability deteriorates (particle-bound radioactivity decreases to 86% within 48 hours)
Solution Approach 1:
The patent changes the chemical state of rhenium from Re(VII) to Re(I) tricarbonyl complex, and modifies the ligands from tin-based to carbon monoxide and water ligands. This parameter change in the rhenium complex's oxidation state and ligand composition fundamentally alters the bonding characteristics, enabling covalent attachment to HSA microspheres while maintaining in vitro stability above 95% after 72 hours.
Solution Approach 2:
The Re(I) tricarbonyl complex acts as an intermediary species that facilitates stable bonding between rhenium and HSA microspheres. The complex contains carbon monoxide ligands that form strong covalent bonds with the microsphere surface, serving as a stable intermediary structure that prevents direct release of radioactive rhenium while maintaining high labeling yield.
2Productivity
If reductive reaction of Re(VII) with Sn(II) is used for labeling, then labeling efficiency is improved, but harmful factors increase due to tin salt release and protein hydrolysis
Solution Approach 1:
The patent extracts and removes the harmful tin salt component from the labeling system entirely. By using Re(I) tricarbonyl complex with carbon monoxide ligands, the method eliminates the need for tin chloride, thereby removing the source of harmful tin salt release and protein hydrolysis while maintaining high labeling efficiency through the covalent bonding mechanism of the tricarbonyl complex.
Solution Approach 2:
The patent converts the potentially harmful acidic conditions required for some labeling methods into a benefit by using the Re(I) tricarbonyl complex, which can be formed under mild conditions. The carbon monoxide ligands provide stable covalent bonding without requiring harsh acidic environments, thus converting what would be harmful conditions into benign or beneficial ones.
3Reliability
If co-precipitation effect of tin hydroxid colloid is used for labeling, then particle-bound radioactivity is improved initially, but in vivo stability deteriorates due to release from microsphere surface
Solution Approach 1:
The patent creates a composite structure where the Re(I) tricarbonyl complex is integrated with HSA microspheres through covalent bonding. The complex forms a stable composite material where the rhenium center is permanently attached to the microsphere surface via carbon monoxide ligands, preventing release in vivo while maintaining high initial particle-bound radioactivity.
Solution Approach 2:
The patent maintains the spherical structure of HSA microspheres while incorporating the Re(I) tricarbonyl complex on the surface. The covalent bonding approach preserves the intact spherical morphology and surface properties of the microspheres, ensuring that the complex remains firmly attached without causing structural degradation or release, thus achieving both initial radioactivity and in vivo stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly enhances the in vitro and in vivo stability of 186/188Re-HSA microspheres, allowing for effective radiotherapy and diagnosis with maintained radioactivity, suitable for multi-dose treatments.
Implementation Method 1
the weakly bound H2O ligands of [186/188Re(OH2)3(CO)3]+ can be rapidly replaced by histidine or cycteine groups with N, O and S electron donors on HSA microspheres. According to this invention, 186/188Re was covalently bound to the surface of HSA microspheres
Implementation Method 2
the amino borane-reduced 188ReO4− was interacted with carbon oxide to form [186/188Re(OH2)3(CO)3]+
Data Source
AI summary
The present invention relates to a method for preparing 186/188Re-labeled human serum albumin (HSA) microspheres by 186/188Re(I)-tricarbonyl ion. This radioactive particle can be subjected to radioembolization for liver tumor. In this method, 186/188Re(I)-tricarbonyl ion (186/188Re(OH2)3(CO)3)+) are employed as a precursor for directly labeling HSA microspheres with 186/188Re at appropriate temperature.